ReviewJournal of clinical medicine2023
The Performance of GALAD Score for Diagnosing Hepatocellular Carcinoma in Patients with Chronic Liver Diseases: A Systematic Review and Meta-Analysis.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis.Gastroenterology · 2025Trial
- Exploratory Comparison of Meld, Meld-Na, and Meld 3.0 Scores for Prognostic Assessment at Diagnosis in Hepatocellular Carcinoma Using Machine Learning Approaches.Digestive diseases and sciences · 2026Article
- Serum Midkine as a Biomarker for Hepatocellular Carcinoma Treatment Response and Prognostication.Journal of clinical laboratory analysis · 2026Article
- GAFAD: A liquid chromatography-tandem mass spectrometry-based model for early hepatocellular carcinoma detection beyond GALAD's limitations.Clinical and molecular hepatology · 2026Article
- AI-guided additive scoring model for differential diagnosis of primary liver cancer.JHEP reports : innovation in hepatology · 2026Article
- Development of a longitudinal predictive model for hepatocellular carcinoma occurrence in patients with chronic hepatitis B.Scientific reports · 2026Article
- Developing blood extracellular vesicle protein biomarkers for hepatocellular carcinoma: mechanisms, methods, and translation.Journal of nanobiotechnology · 2026Review
- Surgery-centered integrated strategies for personalized hepatocellular carcinoma care.Cancer biology & medicine · 2026Review
- Blu-Ray-Based Quantification of CD98+ Extracellular Vesicles for Early Detection of Hepatocellular Carcinoma.Cancers · 2026Article
- Development and validation of a high-confidence diagnostic model integrating ctDNA methylation and serum biomarkers for early-stage hepatocellular carcinoma detection.Molecular biomedicine · 2026Article
- Comparison of diagnostic performance of GAAD, GALAD, and ASAP scores for detecting hepatocellular carcinoma in advanced liver fibrosis patients.Advances in laboratory medicine · 2026Article
- HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort.Journal of hepatology · 2026Article
- Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening.Gastroenterology · 2026Article
- Refining early detection of hepatocellular carcinoma: The promise of the GALAD score.World journal of gastroenterology · 2026Article
- Validation of the GALAD model for diagnosing HBV-related hepatocellular carcinoma in Chinese patients.Clinics (Sao Paulo, Brazil) · 2026Article
- Article
- TASL practice guidance for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD).Hepatology forum · 2026Article
- Assessment of GALAD score as a diagnostic and prognostic factor ofHepatology forum · 2026Article
- Development of a novel diagnostic model integrating microRNAs and GALAD for HBV-related hepatocellular carcinoma.Biomarkers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background GALAD score, comprising five clinical parameters, is a predictive model developed for hepatocellular carcinoma (HCC) detection. Since its emergence, its diagnostic ability has been validated in different populations with a wide variation. Therefore, we conducted a meta-analysis to investigate its overall diagnostic performance in differentiating HCC in chronic liver diseases. Methods Eligible studies were searched in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.